# Phase II Combination Stem Cell Therapy for the Treatment of Severe Coronary Ischemia(CI)

> **NCT00790764** · PHASE2 · SUSPENDED · sponsor: **TCA Cellular Therapy** · enrollment: 60 (estimated)

## Conditions studied

- Heart Disease
- Blocked Arteries
- Coronary Ischemia
- Coronary Disease
- Coronary Artery Disease
- Coronary Atherosclerosis

## Interventions

- **BIOLOGICAL:** MESENDO
- **OTHER:** placebo

## Key facts

- **NCT ID:** NCT00790764
- **Lead sponsor:** TCA Cellular Therapy
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2008-11
- **Primary completion:** 2014-05
- **Final completion:** 2014-05
- **Target enrollment:** 60 (ESTIMATED)
- **Why stopped:** Suspended due to lack of funding.
- **Last updated:** 2014-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00790764

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00790764, "Phase II Combination Stem Cell Therapy for the Treatment of Severe Coronary Ischemia(CI)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00790764. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*